Last reviewed · How we verify
elvitegravir/cobicistat/emtricitabine/Tenofovir-Disoproxil
elvitegravir/cobicistat/emtricitabine/Tenofovir-Disoproxil is a Antiretroviral combination (integrase inhibitor + pharmacokinetic booster + nucleoside/nucleotide reverse transcriptase inhibitors) Small molecule drug developed by Fundacion Clinic per a la Recerca Biomédica. It is currently FDA-approved for HIV-1 infection in treatment-naïve and treatment-experienced adults. Also known as: (Stribild).
This fixed-dose combination inhibits HIV integrase, protease, and reverse transcriptase while blocking viral entry, suppressing HIV replication through multiple mechanisms.
This fixed-dose combination inhibits HIV integrase, protease, and reverse transcriptase while blocking viral entry, suppressing HIV replication through multiple mechanisms. Used for HIV-1 infection in treatment-naïve and treatment-experienced adults.
At a glance
| Generic name | elvitegravir/cobicistat/emtricitabine/Tenofovir-Disoproxil |
|---|---|
| Also known as | (Stribild) |
| Sponsor | Fundacion Clinic per a la Recerca Biomédica |
| Drug class | Antiretroviral combination (integrase inhibitor + pharmacokinetic booster + nucleoside/nucleotide reverse transcriptase inhibitors) |
| Target | HIV integrase, CYP3A4, HIV reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
Elvitegravir is an integrase strand transfer inhibitor that prevents HIV DNA from integrating into the host genome. Cobicistat is a pharmacokinetic booster that inhibits CYP3A4, enhancing elvitegravir levels. Emtricitabine and tenofovir disoproxil are nucleoside/nucleotide reverse transcriptase inhibitors that block viral RNA-dependent DNA polymerase, together providing potent antiretroviral activity against HIV-1.
Approved indications
- HIV-1 infection in treatment-naïve and treatment-experienced adults
Common side effects
- Nausea
- Diarrhea
- Headache
- Elevated creatinine
- Rash
Key clinical trials
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment-Naive Adolescents and Virologically Suppressed Children (PHASE2, PHASE3)
- Trial to Evaluate the Interest of a Reductive Anti Retroviral Strategy Using Dual Therapy Inspite of Triple Therapy (PHASE3)
- Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- Study to Compare an Oral Weekly Islatravir/Lenacapavir Regimen With Standard of Care in Virologically Suppressed People With HIV-1 (PHASE3)
- Early ART to Limit Infection and Establishment of Reservoir (PHASE2)
- Cost-effectiveness of Different Antiretroviral Treatment in Patients HIV Naive (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- elvitegravir/cobicistat/emtricitabine/Tenofovir-Disoproxil CI brief — competitive landscape report
- elvitegravir/cobicistat/emtricitabine/Tenofovir-Disoproxil updates RSS · CI watch RSS
- Fundacion Clinic per a la Recerca Biomédica portfolio CI
Frequently asked questions about elvitegravir/cobicistat/emtricitabine/Tenofovir-Disoproxil
What is elvitegravir/cobicistat/emtricitabine/Tenofovir-Disoproxil?
How does elvitegravir/cobicistat/emtricitabine/Tenofovir-Disoproxil work?
What is elvitegravir/cobicistat/emtricitabine/Tenofovir-Disoproxil used for?
Who makes elvitegravir/cobicistat/emtricitabine/Tenofovir-Disoproxil?
Is elvitegravir/cobicistat/emtricitabine/Tenofovir-Disoproxil also known as anything else?
What drug class is elvitegravir/cobicistat/emtricitabine/Tenofovir-Disoproxil in?
What development phase is elvitegravir/cobicistat/emtricitabine/Tenofovir-Disoproxil in?
What are the side effects of elvitegravir/cobicistat/emtricitabine/Tenofovir-Disoproxil?
What does elvitegravir/cobicistat/emtricitabine/Tenofovir-Disoproxil target?
Related
- Drug class: All Antiretroviral combination (integrase inhibitor + pharmacokinetic booster + nucleoside/nucleotide reverse transcriptase inhibitors) drugs
- Target: All drugs targeting HIV integrase, CYP3A4, HIV reverse transcriptase
- Manufacturer: Fundacion Clinic per a la Recerca Biomédica — full pipeline
- Therapeutic area: All drugs in Infectious Disease / Virology
- Indication: Drugs for HIV-1 infection in treatment-naïve and treatment-experienced adults
- Also known as: (Stribild)
- Compare: elvitegravir/cobicistat/emtricitabine/Tenofovir-Disoproxil vs similar drugs
- Pricing: elvitegravir/cobicistat/emtricitabine/Tenofovir-Disoproxil cost, discount & access